Skip to Content

Additional Content In This Section


Cardiovascular Inflammation Reduction Trial


Status Enrolling

Condition Cardiovascular Disease


The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks,
strokes, or death in people with type 2 diabetes or metabolic syndrome that
have had a heart attack or multiple coronary blockages.


Investigate whether low-dose methotrexate (LDM) will reduce rates of myocardial infarction, stroke, and cardiovascular death among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome.entry and elevated hsCRP will prevent recurrent cardiovascular events. 

Phase III

Key Inclusion Criteria

Documented past history of myocardial infarction OR past evidence of multi-vessel coronary artery disease by angiography and history of type 2 diabetes or metabolic syndrome at time of study enrollment.

Key Exclusion Criteria

  • Prior history of chronic infectious disease
  • Chronic inflammatory condition
  • Women of child bearing potential Identifier


Protocol Number


Principal Investigator(s)
Rabeea Aboufakher, MD

Clinical Trial Categories

  • Cardiology
Brigham and Women’s Hospital
Collaborator: National Heart Lung and Blood Institute
Dianne Vold, LPN CCRC at 701-780-1559